Joshua Richter, Associate Professor of Medicine, Hematology, and Medical Oncology at The Tisch Cancer Institute, shared on X:
“Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma | Regeneron Pharmaceuticals Inc. Read more.”